How valid are animal models to evaluate treatments for pulmonary hypertension?

Author： Campian Maria Hardziyenka Maxim Michel Martin Tan Hanno

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.373, Iss.6, 2006-09, pp. : 391-400

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses

Current Pharmaceutical Design, Vol. 21, Iss. 18, 2015-06 ,pp. : 2422-2439

Bentham Science Publishers

Access to resources Recommend Favorite

Animal Models of Pulmonary Emphysema

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 6, 2005-12 ,pp. : 665-673

Bentham Science Publishers

Access to resources Recommend Favorite

Animal models to evaluate anti‐atherosclerotic drugs

Fundamental & Clinical Pharmacology, Vol. 29, Iss. 4, 2015-08 ,pp. : 329-340

John Wiley & Sons Inc

Access to resources Recommend Favorite

Animal models of chronic obstructive pulmonary disease

By Fricker Michael Deane Andrew Hansbro Philip M

Expert Opinion on Drug Discovery, Vol. 9, Iss. 6, 2014-06 ,pp. : 629-645

Informa Healthcare

Access to resources Recommend Favorite

Role of endothelins in animal models of hypertension: focus on cardiovascular protection

By Moreau Pierre Schiffrin Ernesto L

Canadian Journal of Physiology and Pharmacology, Vol. 81, Iss. 6, 2003-06 ,pp. : 511-521

NRC Research Press

Access to resources Recommend Favorite